QARZIBA

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug QARZIBA contains one active pharmaceutical ingredient (API):

1	Dinutuximab beta UNII 7SQY4ZUD30 - DINUTUXIMAB
	Dinutuximab beta is a chimeric monoclonal IgG1 antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
	Read more about Dinutuximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QARZIBA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX06	Dinutuximab beta	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1744590
ES	Centro de información online de medicamentos de la AEMPS	1171191001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	043759
FR	Base de données publique des médicaments	68429472
GB	Medicines & Healthcare Products Regulatory Agency	356560
HK	Department of Health Drug Office	66900
IL	מִשְׂרַד הַבְּרִיאוּת	8955
IT	Agenzia del Farmaco	045427010
LT	Valstybinė vaistų kontrolės tarnyba	1082908
PL	Rejestru Produktów Leczniczych	100391925
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66236001